ArticleIndian pediatrics2025
Simplifying Strategies to Enable Universal, Decentralized Cord Blood TSH Screening: Lessons from a Tertiary Care Center in North India.
Article in Indian pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Universal Decentralized Cord Blood TSH Screening Should Be Offered as Routine Delivery Care in Limited-Resource Settings.International journal of neonatal screening · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the utility of cord blood thyroid stimulating hormone (CBTSH) for improving the universal newborn screening (UNBS) strategy, and to generate regional normative data.
methodsData of UNBS using CBTSH and cord blood free thyroxine (CBfT4) over two years (01 April 2022 to 31 March 2024) in all inborn deliveries was analyzed using descriptive statistics.
resultsOut of 2218 neonates delivered to 2094 mothers, data was available for 2116 newborns (54.4% males; 68.2% term gestation; 27%, 3.5%, and 0.9% late, early and extreme preemies, respectively; 61% appropriate-for-gestational age). The mean (SD) CBTSH was 7 (5.3) mIU/L (3rd-97th percentiles: 2.6-18.8 mIU/ml); higher in extreme preterms, extremely low birth weight (< 1000 g) and sick babies. Mean (SD) cord blood free thyroxine (CBfT4) was 0.99 (0.2) ng/dL (3rd-97th percentiles: 0.7-1.4 ng/dL), lower in extreme preterms. 58 newborns (recall rate 2.7%) had CBTSH > 20 mIU/L (all had normal CBfT4) and were recalled: 5 did not return, 52/53 were normal on retesting. Only 2/58 newborns had CBTSH > 40 mIU/L: one had confirmed CH. With CBTSH cutoff > 40 mIU/L, recall rate could have been reduced to 0.09%.
conclusionWe propose simplified screening strategies of "retest and recall", and using three CBTSH categories, i.e., (a) < 20 mIU/L: normal, discharge; (b) 20-40 mIU/L: test CBfT4, if < 0.7 ng/dL, do confirmatory venous TSH & fT4 at 72 h age (before discharge); (c) > 40 mIU/L: confirmatory venous TSH & fT4 at 72 h (before discharge): if venous TSH < 20 mIU/L: normal; TSH 20-40 mIU/L or fT4 < 0.7 ng/dL: recall and retest at 7-10 days age. If confirmatory venous TSH is high or fT4 is low, start replacement. This would improve decision-making and minimize burden of unnecessary recalls while ensuring early identification.
Indexed as
Identifiers
40126826What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.